The stock forecast and price targets for Keros Therapeutics, traded under the ticker symbol KROS on the Nasdaq exchange, reflect expectations surrounding its clinical pipeline progress. Equity research analysts providing consensus projections evaluate factors such as upcoming clinical data readouts for its lead programs, including trials for its novel protein therapeutics. Price targets established by healthcare analysts generally indicate potential upside from current trading levels, underpinned by optimism regarding its orphan drug designations and specialized pipeline. However, forecasts remain sensitive to clinical trial execution, regulatory updates, and broader market sentiment toward clinical-stage biotechnology equities.